Merck of Germany's Hunt For MS BTKi Partner Boosted By Evobrutinib Data
German Merck tells Scrip its quest to find a partner for its Bruton’s tyrosine kinase inhibitor evobrutinib should be helped by positive 24-week Phase IIb data in relapsing multiple sclerosis.
You may also be interested in...
The German group is predicting sales of its new MS drug Mavenclad in the mid-triple digit million euro range worldwide in 2019 if all goes well across the Atlantic.
With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.